Trial reportClinical cardiology2011
Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study.
Trial report in Clinical cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Nutritional interventions for heart failure patients who are malnourished or at risk of malnutrition or cachexia: a systematic review and meta-analysis.Heart failure reviews · 2021Pooled it
- Creatine in Health and Disease.Nutrients · 2021Pooled it
- Trial
- Well-Known and Novel Behavioural Risk Factors for Heart Failure.Journal of cardiovascular development and disease · 2026Review
- The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure: mechanisms and therapeutic strategies.Frontiers in pharmacology · 2025Review
- Evaluation of the Coenzyme QArchives of Razi Institute · 2023Article
- Combined Supplementation of Coenzyme QNutrients · 2022Review
- Creatine deficiency and heart failure.Heart failure reviews · 2022Review
- Heart Failure-Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10.Journal of cardiovascular development and disease · 2022Review
- Evaluation of simple antioxidant blood parameters in patients with migraine.Frontiers in neurology · 2022Article
- Role of Coenzyme QAntioxidants (Basel, Switzerland) · 2021Review
- Coenzyme QAntioxidants (Basel, Switzerland) · 2021Review
- Role of Creatine in the Heart: Health and Disease.Nutrients · 2021Review
- Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures.International journal of molecular sciences · 2020Review
- Low Antioxidant Status of Serum Uric Acid, Bilirubin, Albumin, and Creatinine in Patients With Benign Paroxysmal Positional Vertigo.Frontiers in neurology · 2020Article
- Cardiac Cachexia: A Well-Known but Challenging Complication of Heart Failure.Clinical interventions in aging · 2020Review
- Water-soluble CoQ10 as A Promising Anti-aging Agent for Neurological Dysfunction in Brain Mitochondria.Antioxidants (Basel, Switzerland) · 2019Review
- Nutritional Deficiency in Patients with Heart Failure.Nutrients · 2016Review
- Cardiac cachexia: hic et nunc.Journal of cachexia, sarcopenia and muscle · 2016Review
- Amino acids and derivatives, a new treatment of chronic heart failure?Heart failure reviews · 2015Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF). HYPOTHESIS: Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF.
methodsWe conducted a randomized, double-blind, placebo-controlled trial to determine the effect of a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine on exercise tolerance and health-related quality of life. Exercise tolerance was measured as total work capacity (kg·m) and peak oxygen consumption (VO(2), mL/min/kg), both from a cardiopulmonary exercise test. Health-related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q-ter 320 mg + creatine 340 mg (n = 35) or placebo (n = 32) once daily for 8 weeks.
resultsAt multivariate analysis, 8-week peak VO(2) was significantly higher in the active treatment group than in the placebo group (+1.8 ± 0.9 mL/min/kg, 95% CI: 0.1-3.6, P < 0.05). No untoward effects occurred in either group.
conclusionsThis study suggests that oral Q-ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long-term effects of this treatment on functional status and harder outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.